PE20091425A1 - Derivados de aminotiazol - Google Patents

Derivados de aminotiazol

Info

Publication number
PE20091425A1
PE20091425A1 PE2008001973A PE2008001973A PE20091425A1 PE 20091425 A1 PE20091425 A1 PE 20091425A1 PE 2008001973 A PE2008001973 A PE 2008001973A PE 2008001973 A PE2008001973 A PE 2008001973A PE 20091425 A1 PE20091425 A1 PE 20091425A1
Authority
PE
Peru
Prior art keywords
benzothiophene
thiazol
sulfonamide
bromo
aminotiazole
Prior art date
Application number
PE2008001973A
Other languages
English (en)
Inventor
Paul Hebeisen
Eric A Kitas
Rudolf E Minder
Peter Mohr
Hans Peter Wessel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20091425A1 publication Critical patent/PE20091425A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

REFERIDA A COMPUESTOS DERIVADOS DE AMINOTIAZOL DE FORMULA (I), DONDE R1 ES (Ia) O (Ib); X ES S, N-R7 U O; R2 Y R3 SON CADA UNO H, ALQUILO, ALCOXI, ENTRE OTROS; R4 Y R5 SON CADA UNO H, ALCOXI, CICLOALQUILO, ENTRE OTROS; R6 ES H, HALO, HALOALQUILO, ENTRE OTROS; R7 ES H, HALOALCOXI, ALCOXIALQUILO, ENTRE OTROS; R7 ES H, ALQUILO, HIDROXIALCOXI, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-[(5-BROMO-1,3-TIAZOL-2-IL)CARBAMOIL]-5-METIL-1-BENZOTIOFENO-2-SULFONAMIDA; N-[(5-BROMO-1,3-TIAZOL-2-IL)CARBAMOIL]-1-BENZOTIOFENO-2-SULFONAMIDA, N-[(5-BROMO-1,3-TIAZOL-2-IL)CARBAMOIL]-5-FLUOR-3-METIL-1-BENZOTIOFENO-2-SULFONAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A SU PROCEDIMIENTO DE PREPARACION Y A COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN. DICHOS COMPUESTOS SON INHIBIDORES DE FRUCTOSA-6-FOSFATO (FBPasa) SIENDO UTILES PARA EL TRATAMIENTO DE DIABETES MELLITUS TIPO I, DIABETES MELLITUS TIPO II, TRASTORNOS DE GLUCOSA EN AYUNAS, ENTRE OTROS
PE2008001973A 2007-11-30 2008-11-25 Derivados de aminotiazol PE20091425A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07122019 2007-11-30

Publications (1)

Publication Number Publication Date
PE20091425A1 true PE20091425A1 (es) 2009-09-23

Family

ID=40430064

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001973A PE20091425A1 (es) 2007-11-30 2008-11-25 Derivados de aminotiazol

Country Status (14)

Country Link
US (1) US7973051B2 (es)
EP (1) EP2227468A1 (es)
JP (1) JP2011504897A (es)
KR (1) KR20100080853A (es)
CN (1) CN101878211A (es)
AR (1) AR069435A1 (es)
AU (1) AU2008328955B2 (es)
BR (1) BRPI0820622A2 (es)
CA (1) CA2706574A1 (es)
IL (1) IL205751A0 (es)
MX (1) MX2010005824A (es)
PE (1) PE20091425A1 (es)
TW (1) TW200922563A (es)
WO (1) WO2009068467A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101990337B (zh) * 2009-08-03 2014-03-26 联咏科技股份有限公司 可动态维持定电流驱动的光源驱动装置及其相关方法
CN102762575B (zh) 2009-12-04 2015-04-15 桑诺维恩药品公司 多环化合物及其使用方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
EA201990399A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения, композиции и их применение
CN116283877A (zh) 2016-07-29 2023-06-23 赛诺维信制药公司 化合物、组合物及其用途
US11129807B2 (en) 2017-02-16 2021-09-28 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
EA202090414A1 (ru) 2017-08-02 2020-05-28 Суновион Фармасьютикалз Инк. Соединения и их применение
CA3091292A1 (en) 2018-02-16 2019-08-22 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
WO2020002090A1 (de) 2018-06-25 2020-01-02 Bayer Aktiengesellschaft Substituierte thiazolylpyrrolone sowie deren salze und ihre verwendung als herbizide wirkstoffe
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AU2020236225A1 (en) 2019-03-14 2021-09-16 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
MX2022012833A (es) 2020-04-14 2022-11-07 Sunovion Pharmaceuticals Inc (s)-(4,5-dihidro-7h-tieno[2,3-c]piran-7-il)-n-metilmetanamina para tratar trastornos neurologicos y psiquiatricos.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933355A (en) 1988-04-14 1990-06-12 Sankyo Company Limited Thiazole derivatives, their preparation and their use in the treatment of diabetes complications
JP3573757B2 (ja) * 1997-01-29 2004-10-06 ファイザー・インク スルホニルウレア誘導体、およびインターロイキン−１の活性を制御する上でのスルホニルウレア誘導体の使用
DK1257550T3 (da) * 2000-02-04 2006-03-27 Portola Pharm Inc Blodplade-ADP-receptor-inhibitor
JP2005510508A (ja) 2001-11-08 2005-04-21 藤沢薬品工業株式会社 アデノシンアンタゴニストとしてのチアゾールピリダジノン類
BRPI0510095A (pt) 2004-04-20 2007-10-16 Transtech Pharma Inc tiazol substituìdo e derivados de pirimidina como moduladores de receptores de melanocortina
DK200600313A (da) 2006-03-03 2006-03-13 Novo Nordisk As Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor
WO2007137962A1 (en) * 2006-06-01 2007-12-06 F. Hoffmann-La Roche Ag Thiazole derivatives

Also Published As

Publication number Publication date
BRPI0820622A2 (pt) 2015-06-16
AU2008328955A1 (en) 2009-06-04
AR069435A1 (es) 2010-01-20
IL205751A0 (en) 2010-11-30
CN101878211A (zh) 2010-11-03
CA2706574A1 (en) 2009-06-04
EP2227468A1 (en) 2010-09-15
US20090143448A1 (en) 2009-06-04
MX2010005824A (es) 2010-06-11
US7973051B2 (en) 2011-07-05
TW200922563A (en) 2009-06-01
JP2011504897A (ja) 2011-02-17
AU2008328955B2 (en) 2012-12-13
WO2009068467A1 (en) 2009-06-04
KR20100080853A (ko) 2010-07-12

Similar Documents

Publication Publication Date Title
PE20091425A1 (es) Derivados de aminotiazol
AR062111A1 (es) Derivados de beta-d-glucopiranosil indol, metodo de preparacion, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos.
EA201791254A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
DOP2009000133A (es) Derivados de indol como agonistas de los receptores s1p1
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
CL2008001017A1 (es) Compuestos derivados de indol, activadores de glucoquinasa; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de diabetes u obesidad.
PH12013500745A1 (en) Azaadamantane derivatives and methods of use
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
NO20083057L (no) Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer
DK2203430T3 (da) N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
CL2008002768A1 (es) Compuestos derivados de carboxiciclopropil-(bis-fenil-oxamidas); composicion farmaceutica que los contiene; procedimiento para la elaboracion de las composiciones y el uso de los compuestos en el tratamiento de diabetes y trastornos del sncentre otras enfermedades.
NO20065678L (no) 3-(4-heteroarylcykloheksylamino) cyklopentankarboksamider som modulatorer for kjemokinreseptorer.
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
NO20070336L (no) Indolderivater som histamin-reseptorantagonister
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
AR057222A1 (es) Agonistas del receptor del neuropeprtido -2
PE20091426A1 (es) Compuestos de piridina
NO20082285L (no) 3-aminosyklopentankarboksamider som modulatorer av kjemokinreseptorer
UY31554A1 (es) Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet

Legal Events

Date Code Title Description
FA Abandonment or withdrawal